Literature DB >> 12547405

Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells.

Bärbel Abriss1, Günter Hollweg, Axel M Gressner, Ralf Weiskirchen.   

Abstract

BACKGROUND/AIMS: The principal cellular effectors of fibrosis in liver are hepatic stellate cells (HSC). In response to liver injury these quiescent cells undergo a phenotypic change to a myofibroblastic cell type, proliferate and secrete matrix components. Thus, removal of activated HSC should be beneficial for the prognosis of hepatic fibrogenesis and preserve organ function.
METHODS: The purpose of this study was to investigate whether administration of adenoviruses constitutively expressing the p53 tumor suppressor or the retinoblastoma protein (pRb) is sufficient to induce cell arrest or apoptosis in culture-activated HSC. The expression of the transgenes was confirmed by Western blot analysis and immunohistochemistry.
RESULTS: Both proteins were expressed mainly in the nucleus and their expression was associated with a marked inhibition of cell proliferation and induction of apoptosis as determined by measurement of phosphatidylserine exposed at the surface, proliferation assay, induction of the p21 cyclin-dependent kinase inhibitor, and an increase of caspase-3 activity. Additionally, electron microscopic analysis confirmed that activation of the p53-mediated pathway in HSC results in chromatin and cytoplasmic condensation, typical features of ongoing apoptosis.
CONCLUSIONS: Our results indicate that transduction of p53 or pRb offers a feasible approach to induce apoptosis in activated HSC. Thus, targeted transfer of these proteins into HSC may be potentially useful for the treatment of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547405     DOI: 10.1016/s0168-8278(02)00361-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo.

Authors:  Miao Chen; Guang-Ji Wang; Yong Diao; Rui-An Xu; Hai-Tang Xie; Xin-Yan Li; Jian-Guo Sun
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

2.  Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans.

Authors:  E Novo; F Marra; E Zamara; L Valfrè di Bonzo; L Monitillo; S Cannito; I Petrai; A Mazzocca; A Bonacchi; R S M De Franco; S Colombatto; R Autelli; M Pinzani; M Parola
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

3.  Absence of Nogo-B (reticulon 4B) facilitates hepatic stellate cell apoptosis and diminishes hepatic fibrosis in mice.

Authors:  Keitaro Tashiro; Ayano Satoh; Teruo Utsumi; Chuhan Chung; Yasuko Iwakiri
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

4.  KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro.

Authors:  Ping An; Jun-Yong Zhu; Yan Yang; Peng Lv; Yi-Hao Tian; Ming-Kai Chen; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

5.  Association of differentially expressed genes with activation of mouse hepatic stellate cells by high-density cDNA microarray.

Authors:  Xiao-Jing Liu; Li Yang; Feng-Ming Luo; Hong-Bin Wu; Qu Qiang
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

6.  Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb.

Authors:  Md Kaimul Ahsan; Wajahat Z Mehal
Journal:  Front Pharmacol       Date:  2014-04-10       Impact factor: 5.810

7.  Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis.

Authors:  Sabrina Cipriani; Adriana Carino; Dario Masullo; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.